Article

Research supporting ClarityDX Prostate published in Nature Digital Medicine

2024-07-03T19:51:25+00:00
Published 26 June 2024

Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform

M. Eric Hyndman, Robert J. Paproski, Adam Kinnaird, Adrian Fairey, Leonard Marks, Christian P. Pavlovich, Sean A. Fletcher, Roman Zachoval, Vanda Adamcova, Jiri Stejskal, Armen Aprikian, Christopher J. D. Wallis, Desmond Pink, Catalina Vasquez, Perrin H. Beatty & John D. Lewis

Abstract
The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification of csPCa while avoiding unnecessary biopsies in men with non-csPCa is challenging. We built an optimized machine learning platform (ClarityDX) and showed its utility in generating models predicting csPCa. Integrating the ClarityDX platform with blood-based biomarkers for clinically significant PCa and clinical biomarker data from a 3448-patient cohort, we developed a test to stratify patients’ risk of csPCa; called ClarityDX Prostate. When predicting high risk cancer in the validation cohort, ClarityDX Prostate showed 95% sensitivity, 35% specificity, 54% positive predictive value, and 91% negative predictive value, at a ≥ 25% threshold. Using ClarityDX Prostate at this threshold could avoid up to 35% of unnecessary prostate biopsies. ClarityDX Prostate showed higher accuracy for predicting the risk of csPCa than PSA alone and the tested model-based risk calculators. Using this test as a reflex test in men with elevated PSA levels may help patients and their healthcare providers decide if a prostate biopsy is necessary.
Research supporting ClarityDX Prostate published in Nature Digital Medicine2024-07-03T19:51:25+00:00

Nanostics Prostate Cancer Screening Test, ClarityDX Prostate®, becomes accessible to men in British Columbia, Saskatchewan, and Ontario

2024-06-05T14:30:41+00:00

EDMONTON, AB, June 5, 2024 /CNW/ – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is thrilled to announce today that men can now provide blood samples for its ClarityDX Prostate test at LifeLabs collection sites across British Columbia, Saskatchewan, and Ontario.

ClarityDX Prostate uses biological data, clinical information, and machine learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy or not following a high prostate-specific antigen (PSA) test result.

“We are very happy that we can now bring a powerful tool in prostate cancer screening to men and their healthcare providers in BC, Saskatchewan, and Ontario“, said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “When a doctor orders this test for their patient, they will receive accurate information about his risk of aggressive prostate cancer, helping make informed treatment decisions and avoid unnecessary invasive prostate biopsies.”

ClarityDX Prostate is available in British Columbia, Saskatchewan, and Ontario as a laboratory-developed test from Nanostics Clinical Laboratory in Edmonton, Alberta. In these provinces, tests are ordered, analyzed, and reported to the prescribing healthcare provider by Nanostics.

Go to www.nanosticsdx.com for more information and to order ClarityDX Prostate. Please direct all inquiries about the ClarityDX Prostate test to Nanostics via email at info@nanosticsdx.com or telephone 1-800-672-2027. ClarityDX Prostate is also available in Alberta from Nanostics as well as in Quebec from CDL Laboratories.

Click on the link below to read the full press release.

Nanostics Prostate Cancer Screening Test, ClarityDX Prostate®, becomes accessible to men in British Columbia, Saskatchewan, and Ontario2024-06-05T14:30:41+00:00

Nanostics partners with CDL Laboratories to Provide Access to ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer

2024-05-22T12:15:29+00:00
  • Quebec-based CDL Laboratories will now offer the validated ClarityDX Prostate risk score to healthcare providers and their patients suspected of having aggressive prostate cancer.
  • ClarityDX Prostate combines biological and clinical information using AI-powered learning to generate a risk score for aggressive prostate cancer.

EDMONTON, ALBERTA – May 22 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, signed an agreement with Quebec-based CDL Laboratories (CDL) to expand access to the ClarityDX Prostate® to men and their healthcare providers.

ClarityDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy or not following a high prostate-specific antigen (PSA) test result.

Click on the link below to read the full press release.

Nanostics partners with CDL Laboratories to Provide Access to ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer2024-05-22T12:15:29+00:00

Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test

2024-04-23T12:23:50+00:00
  • University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test
  • ClarityDX Prostate is a blood test that combines biological and clinical information using machine learning to generate a risk score for aggressive prostate cancer

EDMONTON, ALBERTA – April 23 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today that it received an investment from the University of Alberta Innovation Fund (UAIF) to help propel adoption of Nanostics’ ClarityDX Prostate® test in North America.

Funds raised through the UAIF will go towards expanding access to ClarityDX Prostate across North America and supporting the expansion of its product pipeline, including the development of ClarityDX Bladder, a minimally invasive bladder cancer diagnostic test.

ClarityDX Prostate is currently available in Canada as a laboratory-developed test. For more information or to order the test please visit nanosticsdx.com.

Click below to read the full press release.

Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test2024-04-23T12:23:50+00:00

Prostate Cancer Screening in 2024

2024-04-22T23:57:03+00:00

Dr. Chris Wallis talks about the benefits and harms of prostate cancer screening in 2024 using PSA and the addition of adjunctive tests like ClarityDX Prostate.

Prostate Cancer Screening in 20242024-04-22T23:57:03+00:00

Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseases

2024-04-11T17:16:42+00:00
  • Nanostics and Alberta Health Services (AHS) agreement enables collaboration with AHS data scientists to develop new tools to improve the diagnosis of urological diseases.
  • This collaboration will leverage Alberta’s comprehensive digital healthcare assets to improve patient care while satisfying all AHS privacy concerns.

EDMONTON, ALBERTA – April 9th – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is excited to announce a partnership with Cancer Care Alberta, Alberta Health Services (AHS) to leverage advanced data analytics from Connect Care and the Cancer Care Alberta Data Environment for Cancer Inquiries and Decisions (DECIDe). This agreement will streamline access to Connect Care’s powerful and consolidated “one record, one patient, one health clinical information system” to help drive diagnostic and prognostic innovations in urological care in Alberta.

Click below to read the full press release.

Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseases2024-04-11T17:16:42+00:00

ClarityDX Prostate Breakthrough Prostate Cancer Test

2024-04-22T23:51:02+00:00

ClarityDX Prostate is a breakthrough test that significantly advances prostate cancer screening. It provides critical support to men and their primary care providers in making more informed decisions, with 3X the accuracy, about whether a biopsy is required following a high prostate-specific antigen (PSA) test result.

ClarityDX Prostate Breakthrough Prostate Cancer Test2024-04-22T23:51:02+00:00

ClarityDX Prostate is Revolutionizing Prostate Cancer Detection

2024-01-10T22:05:14+00:00

Disruption Magazine Special Issue 21

A Better Way: How Nanostics is Revolutionizing Prostate Cancer Detection

“Any jurisdiction in the world can adopt our test. It’s got huge potential.” Nanostics Chief Commercialization Officer Colin Coros

In the realm of medical innovation, success stories often find their roots in personal journeys. Such is the case with Nanostics, a pioneering company in the field of prostate cancer diagnostics. The tale begins with Frank Sojonky, an Alberta businessman, who, upon facing a prostate cancer diagnosis, embarked on a mission to revolutionize the landscape of prostate cancer research and testing.

Sojonky’s dissatisfaction with the lack of focus on prostate cancer research in Alberta led to the creation of the Bird Dogs for Prostate Cancer Research organization in partnership with the Alberta Cancer Foundation. The organization ultimately raised more than $20 million to establish a translational research program, known as the Alberta Prostate Cancer Research Initiative, headed by CEO Dr. John Lewis. It evolved into the world’s largest repository for prostate cancer patient samples, and with a focus on translation, those samples became instrumental in developing new therapeutics and diagnostic tests.

Click below to read the full article.

ClarityDX Prostate is Revolutionizing Prostate Cancer Detection2024-01-10T22:05:14+00:00

Follow Us

Follow us in real-time to learn about our products and what’s in the developmental pipeline.

Contact Us

Nanostics clinical laboratory is located at 10150 102 Street, Edmonton, AB, Canada.

Hours: 9 am – 5 pm Monday to Friday

If you have questions or concerns please contact us by telephone or email. We will respond within 1 to 2 business days.

Telephone: 1-800-672-2027

  • Press 1 to connect with the Clinical Laboratory

  • Press 2 for help with ordering your ClarityDX Prostate test

  • Press 3 for General Inquiries.

Email info@nanosticsdx.com or submit a message in the Contact Us box to the right.

We value your privacy, please read our policy here: Nanostics Privacy Policy

    © Copyright 2024 Nanostics | Designed by Forward Momentum | Powered by WordPress

    Go to Top